AVE-1642 is under clinical development by ImmunoGen and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AVE-1642’s likelihood of approval (LoA) and phase transition for Graves’ Ophthalmopathy took place on 28 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AVE-1642 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AVE-1642 overview

AVE-1642 was under development for the treatment of recurrent, refractory multiple myeloma, advanced or metastatic liver carcinoma and advanced hormono-dependent breast cancer. AVE1642 is administered as an intravenous infusion. AVE1642 is a humanized monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R/CD221) with potential antineoplastic activity. The drug candidate is developed by using proprietary TAP technology.

ImmunoGen overview

ImmunoGen is a clinical-stage biotechnology company that focuses on the development of novel antibody-drug conjugates (ADCs) that facilitate targeted therapies for the treatment of cancer. Its pipeline product candidates include mirvetuximab soravtansine for the treatment of platinum-resistant ovarian cancer; IMGN632 for AML, and blastic plasmacytoid dendritic cell neoplasm (BPDCN); IMGC936, the company’s product candidate for a range of solid tumors; and IMGN151, its next-generation anti-FRa candidate in the preclinical development stage. ImmunoGenorporates its proprietary product development ADC technology to enhance the anticancer activity of monoclonal antibodies. The company has direct operations in the US, Ireland, and the UK. ImmunoGen is headquartered in Waltham, Massachusetts, the US.

Quick View AVE-1642 LOA Data

Report Segments
  • Innovator
Drug Name
  • AVE-1642
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.